10589 Berlin, de
+49 (30) 726-2470
Noxxon Pharma Licenses and Assigns Preclinical Spiegelmer® Programs to Aptarion
Noxxon Continues Transition to Clinical Oncology Company
NOXXON has maintained exclusive rights to Spiegelmers binding to the targets of its clinical-stage programs. Otherwise, the agreement allows both companies to use the Spiegelmer® technology, and a cross-licensing provision provides for continued access to new enabling inventions to be used by both companies.
“This agreement is another step on the transition of NOXXON to a clinical-stage oncology company. With our focus on clinical development of our programs in oncology, we made the decision to spin-out the other assets and this agreement with Aptarion is, we believe, the best opportunity to see them successfully developed.” commented Aram Mangasarian, CEO of NOXXON.
The use of information published here for personal information and editorial processing is generally free of charge. Please clarify any copyright issues with the stated publisher before further use. In the event of publication, please send a specimen copy to firstname.lastname@example.org.